.png){kind=icon}
返回
.png){kind=icon}
.png){kind=icon}
摘要
En 中文
Fezolinetant (VEOZAH & TRADE;) is an oral, small molecule, neurokinin 3 receptor (NK3R) antagonist, which is being developed by Astellas Pharma Inc. for the treatment of moderate to severe vasomotor symptoms (VMS) or hot flashes due to menopause. Inhibiting NK3R-mediated signalling in the central nervous system is a non-hormonal strategy to modulate the activity of neurones that are associated with thermoregulation, thereby reducing the frequency and severity of VMS. Fezolinetant received its first approval in the USA in May 2023 for the treatment of moderate to severe VMS due to menopause. This article summarizes the milestones in the development of fezolinetant leading to this first approval in this indication.
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
暂无机构信息
引用论文
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled studyFezolinetant用于治疗与绝经相关的中度至重度血管舒缩症状 (SKYLIGHT 1): 一项3期随机对照研究.png)
LANCET.png)
LANCETIF88.5
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏
没有更多内容
没有更多内容